ClinicalTrials.gg
Not yet recruitingNCT07533227FMT-CACHUpdated Apr 16, 2026

Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia

A Phase 2 interventional study of FMT capsule in Cachexia; Cancer and Fecal Microbiota Transplantation (FMT), sponsored by Hua Jiang. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Hua Jiang · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This project is a prospective, multicenter, single-arm, phase II clinical study aimed at evaluating the efficacy and safety of fecal microbiota transplantation (FMT) in treating advanced tumor cachexia.

Read the detailed description

This study intends to include 66 patients with advanced gastric cancer, colorectal cancer, and lung cancer suffering from cachexia (including the pre-cachexia stage and the cachexia stage), who have received second-line or higher treatment. The patients will undergo a 12-week intervention of fecal microbiota transplantation. Fecal microbiota capsules will be orally administered at three time points: Day 0, Day 28, and Day 56. Blood and fecal samples will be collected at three time points: Day 0, Day 28, and Day 84 for metagenomic and metabolomic testing. Abdominal weight will be measured at four time points: Day 0, Day 28, Day 56, and Day 84. The above time points can be advanced or postponed by up to 3 days. The FAACT A/CS anorexia assessment scale and the Brief Fatigue Scale will be filled out. Liver function and CRP will be tested. The primary endpoint is the change in body weight compared to the baseline at 12 weeks (Day 84). The secondary endpoints include: the improvement in albumin, prealbumin, CRP, appetite, and fatigue compared to the baseline at 12 weeks, as well as safety.

02

Conditions studied

  • Cachexia; Cancer
  • Fecal Microbiota Transplantation (FMT)

Keywords

  • cachexia
  • FMT
  • Fecal Microbiota Transplantation
03

In context

Cachexia

331 studies on the registry are indexed under Cachexia; 75 are open to participants now.

This study's planned enrollment of 66 is below the median of 74 across 226 interventional studies indexed under Cachexia.

Browse Cachexia studies →

Lead sponsor

Hua Jiang is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre-advanced or advanced tumor cachexia stage.
  2. Age ≥ 18 years old, score 0-2, expected survival > 3 months.
  3. Patients with gastric cancer, colorectal cancer, or lung cancer who have received or higher treatment.
  4. No FMT treatment in the past six months.

Exclusion criteria

Exclusion Criteria:

  1. Any condition that affects gastrointestinal absorption, such as difficulty in swallowing, malabsorption, or uncontrollable vomiting; undergoing tube feeding or parenteral nutrition.
  2. Neurotic anorexia, anorexia caused by mental illness, or difficulty in eating due to pain.
  3. Acquired immunodeficiency syndrome.
  4. Currently taking or planning to take other drugs that increase appetite or weight, such as adrenal (except for short-term use of dexamethasone during chemotherapy), androgens, progestogens, salidroside, olanzapine, and anamorin or other appetite stimulants.
  5. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with difficult-to-control diabetes.
  6. Current imaging or clinical manifestations of gastrointestinal obstruction.
  7. Current uncontrolled coexisting diseases, including but not limited to decompensated cirrhosis, renal failure, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or mental illnesses/societal conditions that may limit patient compliance with study requirements or affect the patient's ability to provide written .
  8. Within 12 months prior to the first administration, there was unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or above according to the functional classification), or vascular diseases (such as aneurysms with a risk of rupture), or other cardiac damages that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmias, myocardial ischemia); within 6 months prior to the first administration, there was esophageal-gastric varices, severe ulcers, gastrointestinal perforation and/or fistula history, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess or history of acute gastrointestinal bleeding.
  9. Within 4 weeks prior to the first administration, a serious infection occurred, including but not limited to conditions requiring hospitalization.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    FMT

    Drug: FMT capsule

Interventions

  • Fecal microbiota capsules will be orally administered at three time points: Day 0, Day 28, and Day 56.

06

What researchers measure

Primary outcomes

  1. Fasting weight

    Time frame: Day 0, Day 28, Day 56, Day 84

Secondary outcomes

  1. Albumin

    Time frame: Day 0, Day 28, Day 56, Day 84

  2. Prealbumin

    Time frame: Day 0, Day 28, Day 56, Day 84

  3. CRP

    Time frame: Day 0, Day 28, Day 56, Day 84

  4. Appetite

    FAACT A/CS anorexia assessment scale

    Time frame: Day 0, Day 28, Day 56, Day 84

  5. Fatigue

    Brief Fatigue Scale

    Time frame: Day 0, Day 28, Day 56, Day 84

  6. Safety (Adverse event)

    Time frame: Day 0, Day 28, Day 56, Day 84

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07533227
Lead sponsor
Hua Jiang
Responsible party
Hua Jiang (Head of oncology department, Changzhou No.2 People's Hospital) — Sponsor-investigator
First posted
Apr 16, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Hua Jiang, Prof.
Contact
czeyjh@njmu.edu.cn
+86 18015852711
Qin, Dr.
Contact
110329776@qq.com
+86 18351975061

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fecal microbiota

Start the discussion